VetMedTreating subclinical Rhodococcus equi pneumonia in foals: does antimicrobial treatment vs monitoring improve progression or resolution, or mainly add resistance pressure? — LIKELY (the treatment made no difference)
In foals with subclinical ultrasonographic Rhodococcus equi lesions, does antimicrobial treatment vs monitoring shorten lesions or merely add cost and resistance?
Shelf #825 · gate-verified and displayed under the developer's blinded-trial rule
LIKELY (the treatment made no difference): Two randomised, blinded, placebo-controlled trials from the same endemic-farm research programme agree that treating subclinical ultrasonographic pulmonary abscesses with antimicrobials does not improve recovery over placebo/monitoring. In Venner 2012 (PMID: 21924651; 128 foals with abscesses ≥ 1.0 cm in diameter, randomly allocated to tulathromycin, azithromycin, azithromycin with rifampin, or an oral glucose placebo, with weekly examinations by individuals unaware of group assignment), 14/32 (43.8%) of placebo foals recovered without any therapy, and the proportion responding to initial therapy, duration of therapy, kinetics of ultrasonographic lesion resolution, and the proportion and timing of removals for worsening did not differ significantly between treatment groups. In Venner 2013 (PMID: 23278131; controlled, randomized, double-blinded; 108 foals with abscesses of 5.0–10 cm in diameter across five groups including an intramuscular saline placebo), 22/25 (88%) of placebo foals recovered without treatment, the proportion with disease progression did not differ significantly between groups (P > .05), and the timeframe of ultrasonographic lesion resolution did not differ significantly — the one differing endpoint was median duration of treatment, shorter with azithromycin–rifampin (46 days) than with placebo (73 days) (P < .05), a process measure that did not translate into faster lesion resolution. A later cohort study on a single stud farm supports waiting: Boeger 2026 (PMID: 41722849; 1,200 screening-diagnosed foals) found that raising the treatment threshold from an abscess score of ≥ 15.0 cm to ≥ 20.0 cm cut the proportion of foals treated from 29.0% to 17.5%, with mortality unchanged at 1.0% in both periods and no statistical difference in treatment failure or recurrence. The resistance half of the question is answered observationally: Huber 2021 (PMID: 33683955) found soil concentrations of macrolide- and rifampicin-resistant R. equi were significantly higher on farms that screened by thoracic ultrasonography and treated subclinical foals (summed mean 8.85 log10-transformed CFU/g) than on farms that did not (7.37) — an association at farm level, not a randomised comparison. No carded record measures monetary cost directly. Design class (a): randomisation and blinding are established by the carded Venner 2013 record (record wording 'controlled, randomized, and double-blinded') answering this shelf's own comparison — antimicrobial treatment versus placebo — in this shelf's own population, subclinically affected foals. The stamp is LIKELY, not PROBABLE, because both placebo-controlled trials come from one farm and one research group, severe lesions and foals in respiratory distress were excluded, and lesions were ultrasonographic on endemic farms rather than culture-confirmed in every foal; and the null is stated for progression and resolution, the outcomes the trials measured — it is not a claim that no individual foal ever benefits, and foals that worsened in these studies were removed and treated. Tier C is not engaged: no mortality or survival BENEFIT is claimed; mortality appears only as an unchanged outcome in the cohort card. Drafted Nov 10, 2026 (VetMed build, topic #825); all figures from the abstracts fetched and verified at drafting.
Venner 2012: antimicrobial treatment did not hasten recovery of subclinical pulmonary abscesses versus glucose placebo — 43.8% of placebo foals recovered with no therapy at all (the treatment made no difference)
Randomised placebo-controlled trial with blinded outcome assessment (record: foals randomly allocated; examinations performed by individuals unaware of treatment group assignment; MeSH includes Double-Blind Method; publication types: Journal Article, Randomized Controlled Trial)
Who: Foals: 128 foals with ultrasonographic evidence of pulmonary abscesses ≥ 1.0 cm in diameter on a farm with endemic Rhodococcus equi infections. Animals with respiratory distress or severe pulmonary lesions were excluded. Foals were randomly allocated to one of four equal treatment groups: (1) tulathromycin intramuscularly; (2) azithromycin monotherapy orally; (3) azithromycin in combination with rifampin orally; and (4) glucose orally as a placebo. Physical examination, thoracic ultrasonography and white blood cell counts were performed weekly by individuals unaware of treatment group assignment; foals that worsened were removed from the study and treated with azithromycin and rifampin.
Result: Overall, 14/32 (43.8%) foals in the placebo group recovered without the need for therapy. The proportion of foals that responded to the initial therapy, the duration of therapy, the kinetics of ultrasonographic lesion resolution, the proportion of foals that had to be removed from the study and the number of days to removal from the study did not differ significantly between treatment groups (the treatment made no difference). The authors conclude that many foals with pulmonary abscesses recover without antimicrobial therapy and that treatment of sub-clinically affected foals with antimicrobial agents did not significantly hasten recovery.
Watch out: SCOPE: one endemic farm, and only subclinical foals — respiratory distress and severe pulmonary lesions were excluded at entry, so this result does not cover clinical pneumonia or large/severe lesions; lesions of the smaller size class (≥ 1.0 cm) are the population. Lesion attribution to R. equi is ultrasonographic on an endemic farm, not culture confirmation in every foal. 'Recovered without therapy' means without antimicrobials — placebo foals were still monitored weekly, and worsening foals were rescued with azithromycin–rifampin.
Venner M, Rödiger A, Laemmer M, Giguère S. Failure of antimicrobial therapy to accelerate spontaneous healing of subclinical pulmonary abscesses on a farm with endemic infections caused by Rhodococcus equi. Vet J. 2012;192(3):293-8. PMID: 21924651. Registry ID: none in the record. MeSH: Actinomycetales Infections/drug therapy/veterinary* · Animals · Anti-Bacterial Agents/administration & dosage/therapeutic use* · Azithromycin/administration & dosage/therapeutic use · Disaccharides/administration & dosage/therapeutic use · Double-Blind Method · Drug Therapy, Combination · Endemic Diseases/veterinary · Female · Heterocyclic Compounds/administration & dosage/therapeutic use · Horse Diseases/drug therapy* · Horses · Lung Abscess/drug therapy/microbiology/veterinary* · Male · Rhodococcus equi* · Rifampin/administration & dosage/therapeutic use · Time Factors · Treatment Failure · Macrolides
Venner 2013: 88% of saline-placebo foals with subclinical abscesses recovered untreated, and disease progression did not differ between four antimicrobial protocols and placebo (P > .05) (the treatment made no difference)
Controlled, randomized, double-blinded prospective study (record's own wording; publication types: Journal Article, Randomized Controlled Trial)
Who: Foals: 108 foals on a farm endemic for Rhodococcus equi infections, with ultrasonographic evidence of pulmonary abscesses 5.0–10 cm in diameter (record's wording), in a controlled, randomized, and double-blinded prospective study. Foals were randomly allocated to 5 treatment groups: (1) tulathromycin intramuscularly; (2) doxycycline monotherapy orally; (3) doxycycline with rifampin orally; (4) azithromycin with rifampin orally; and (5) saline intramuscularly as a placebo. Physical examination and thoracic ultrasonography were performed by individuals unaware of treatment group assignment; foals with evidence of disease progression were removed and treated with azithromycin–rifampin.
Result: Overall, 22/25 (88%) foals in the placebo group recovered without the need for treatment. The proportion of foals that had evidence of disease progression did not differ significantly between the treatment groups (P > .05) (the treatment made no difference). Although the median duration of treatment was significantly (P < .05) shorter in foals treated with azithromycin–rifampin (46 days) compared with foals treated with placebo (73 days), the time frame of ultrasonographic lesion resolution did not differ significantly between the treatment groups. The authors conclude that the majority of foals with subclinical pulmonary abscesses < 10 cm in diameter recover without antimicrobial treatment and that treatment does not provide a clear benefit over administration of a placebo.
Watch out: Same farm and research group as Venner 2012 — the two trials are consistent but not independent settings. The shorter median 'duration of treatment' on azithromycin–rifampin (46 vs 73 days) is the one endpoint that differed, and it did not come with faster ultrasonographic resolution; do not quote this trial as showing treatment shortens the disease. Foals were subclinical at entry despite the larger lesion-size class, and progressing foals were removed and treated.
Venner M, Astheimer K, Lämmer M, Giguère S. Efficacy of mass antimicrobial treatment of foals with subclinical pulmonary abscesses associated with Rhodococcus equi. J Vet Intern Med. 2013;27(1):171-6. PMID: 23278131. Registry ID: none in the record. MeSH: Actinomycetales Infections/drug therapy/veterinary* · Animals · Anti-Bacterial Agents/therapeutic use* · Double-Blind Method · Female · Horse Diseases/drug therapy*/microbiology · Horses · Lung Abscess/drug therapy/veterinary* · Male · Rhodococcus equi* · Treatment Outcome
Huber 2021: farms that screened foals by ultrasonography and treated subclinical pneumonia with macrolides and rifampin had higher soil concentrations of macrolide- and rifampicin-resistant R. equi than farms that did not (8.85 vs 7.37 log10-transformed CFU/g)
Observational farm-level comparison study (publication types: Journal Article)
Who: Horse-breeding farms: 20 farms in central Kentucky — 10 that used thoracic ultrasonographic screening (TUS) to identify foals with subclinical pneumonia and gave macrolides and rifampin to affected foals, and 10 that did not. 720 soil samples were collected in January, March, May and July 2019 for culture and susceptibility testing, alongside questionnaires about the 2019 foaling season.
Result: Overall, the sum of the mean soil concentrations of macrolide- and rifampicin-resistant Rhodococcus equi was significantly higher for TUS farms (8.85 log10-transformed CFUs/g) versus non-TUS farms (7.37 log10-transformed CFUs/g). The authors conclude that farms using TUS combined with antimicrobial treatment of subclinically affected foals select for antimicrobial-resistant R. equi strains, note that prognosis is worse for foals infected with resistant versus nonresistant strains, and recommend prudent use of antimicrobials for subclinical pulmonary lesions attributed to R. equi.
Watch out: ASSOCIATION, NOT RANDOMISATION: farms chose their own screening practice, so other differences between farms could contribute; the outcome is an environmental (soil) concentration of resistant organisms, not a foal-level clinical outcome, and the figures are log10-transformed concentrations, not proportions of resistant isolates. This card addresses the resistance consequence of a screen-and-treat policy; it does not by itself show that any individual treated foal fares worse.
Huber L, Giguère S, Hart KA, Slovis NM, Greiter ME, Dailey CA, Cohen ND. Association between antimicrobial treatment of subclinical pneumonia in foals and selection of macrolide- and rifampicin-resistant Rhodococcus equi strains at horse-breeding farms in central Kentucky. J Am Vet Med Assoc. 2021;258(6):648-653. PMID: 33683955. Registry ID: none in the record. MeSH: Actinomycetales Infections*/drug therapy/veterinary · Animals · Farms · Horse Diseases*/drug therapy · Horses · Kentucky/epidemiology · Macrolides/therapeutic use · Rhodococcus* · Rhodococcus equi* · Rifampin/therapeutic use
Boeger 2026: delaying antimicrobial treatment until foals reached a higher lesion threshold cut the proportion treated from 29.0% to 17.5%, with mortality unchanged at 1.0% in both periods and no statistical difference in treatment failure or recurrence
Cohort study comparing treatment-threshold periods (record's own methods wording; publication types: Journal Article, Review)
Who: Foals: 1,200 warmblood foals born in 2020, 2022, 2023 and 2024 on a single stud farm, all diagnosed with bronchopneumonia under a screening programme of weekly clinical, haematological and thoracic ultrasonographical examinations; diagnosis required a total abscess score (sum of abscess diameters) ≥ 1.0 cm. The treatment threshold was an abscess score of ≥ 15.0 cm in 2020/2022 and ≥ 20.0 cm in 2023/2024. Treated foals (n = 279) received rifampin/tulathromycin.
Result: The proportion of foals treated decreased significantly from 29.0% in 2020/2022 to 17.5% in 2023/2024, whilst mortalities remained unchanged (both 1.0%). There was no statistical difference in the proportions of foals with treatment failure (2.8% in 2020/2022 vs 8.6% in 2023/2024) and recurrence (2.3% in 2020/2022 vs 0.95% in 2023/2024). The initial treatment duration increased from 21 days (2020/2022) to 25 days (2023/2024). The authors conclude that initiating antimicrobial therapy at a later stage of bronchopneumonia significantly reduced the proportion of foals treated, with failure, recurrence and mortality remaining comparable.
Watch out: NOT RANDOMISED: the threshold changed by calendar period, so year-to-year differences (pathogen pressure, weather, management) can confound the comparison — the foals were randomly SELECTED for the cohort, not randomly allocated to a threshold. The failure point estimate was numerically higher in the later-treatment period (8.6% vs 2.8%) without reaching statistical significance, so 'no statistical difference' should not be read as proof of exact equivalence. Diagnosis was by ultrasonographic abscess score under a screening programme; the record does not report culture confirmation of R. equi for each foal. This card supports a monitor-and-delay strategy; it is not a treat-versus-never-treat trial.
Boeger L, Volkmann N, Probst J, Kemper N, Venner M. More conservative use of antimicrobials does not adversely affect treatment outcomes in foal bronchopneumonia. Vet J. 2026;316:106605. PMID: 41722849. Registry ID: none in the record. MeSH: Animals · Horses · Bronchopneumonia*/veterinary/drug therapy · Horse Diseases*/drug therapy/microbiology · Anti-Bacterial Agents*/therapeutic use · Treatment Outcome · Macrolides/therapeutic use · Rifampin/therapeutic use · Female · Male · Cohort Studies · Disaccharides · Heterocyclic Compounds
Synthesis: two blinded placebo-controlled trials find treatment does not speed resolution of subclinical lesions, a threshold cohort finds later treatment safe, and screen-and-treat farms carry more resistant R. equi in soil — LIKELY (the treatment made no difference)
Synthesis
Who: Synthesis of the four cards above (Venner 2012, 128 foals; Venner 2013, 108 foals; Huber 2021, 20 farms; Boeger 2026, 1,200 foals) and of the near-miss record documented in the result, which was fetched at drafting and deliberately not carded as a claim-carrier.
Result: (1) Treat vs monitor: the placebo arms of the two randomised trials are the monitoring strategy under weekly surveillance — 43.8% (lesions ≥ 1.0 cm) and 88% (lesions 5.0–10 cm) of placebo foals recovered with no antimicrobial at all, and no antimicrobial protocol beat placebo on progression, response or lesion-resolution kinetics. (2) The one randomised record not carded, Cohen 2015 (PMID: 25868480), compared two TREATMENTS with each other in 54 foals with subclinical pulmonary abscesses > 1 cm in diameter — gallium maltolate orally vs clarithromycin combined with rifampin — and found resolution within 28 days in 70% (14/20) of gallium-maltolate foals and 74% (25/34) of clarithromycin–rifampin foals, failing to demonstrate noninferiority overall; with no untreated arm it cannot answer treat-versus-monitor, and its treated resolution proportions sit in the same range as the spontaneous recovery seen in the placebo arms above. (3) Cost: no carded or fetched record reports monetary cost; the documented price of routine treatment is antimicrobial exposure and resistance selection (Huber 2021), plus treatment courses lasting a median of 46–73 days in the 2013 trial. (4) Design class (a): randomisation and blinding are established by Venner 2013 (controlled, randomized, double-blinded) for the treatment-versus-placebo comparison in subclinical foals, corroborated by Venner 2012 (random allocation, assessors unaware of group). The LIKELY stamp reflects two consistent blinded placebo-controlled trials tempered by their single-farm, single-group origin and the exclusions on both trial cards.
Watch out: One-home check at drafting: none of PMIDs 21924651, 23278131, 33683955, 41722849 or 25868480 appears in any other pack on disk. Do not transport this shelf to clinical R. equi pneumonia: every placebo-controlled record here enrolled SUBCLINICAL foals under weekly ultrasonographic monitoring with rescue treatment on worsening — monitoring in these studies is an active surveillance programme, not neglect, and foals with respiratory distress or severe lesions were excluded from the trials.
Synthesis of Venner M et al. PMID: 21924651; Venner M et al. PMID: 23278131; Huber L et al. PMID: 33683955; Boeger L et al. PMID: 41722849; Cohen ND et al. PMID: 25868480. Registry IDs as on the individual cards (none in the records).
Back to the library index · VetMed home
VetMed is an educational resource, not veterinary advice.